131 related articles for article (PubMed ID: 2323615)
21. Long term results of cyclophosphamide, adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer.
Harding M; Milsted R; Hole D; Cordiner J; Barr W; Soukop M; Kennedy J; Soutter WP; Kaye S
Ann Oncol; 1991 Mar; 2(3):231-3. PubMed ID: 2043495
[TBL] [Abstract][Full Text] [Related]
22. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
23. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
24. Intraperitoneal cisplatin with intravenous cyclophosphamide and doxorubicin for previously untreated stage III and IV ovarian carcinoma.
Young JA; Garretson F; Westlake DL; Illig WP; Vogl SE
Cancer Invest; 1989; 7(6):565-70. PubMed ID: 2630007
[TBL] [Abstract][Full Text] [Related]
25. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
26. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
27. Adriamycin and cis-platinum in advanced ovarian cancer.
de Gramont A; Drolet Y; Lavoie A; Painchaud M; Blouin R; Tessier C; Ouellet P
Eur J Cancer Clin Oncol; 1985 Jun; 21(6):665-9. PubMed ID: 4040466
[TBL] [Abstract][Full Text] [Related]
28. Treatment of stages II, III and IV primary surface epithelial ovarian cancers by maximum bulk tumour reduction and combined chemotherapy with cyclophosphamide, doxorubicin and cisplatin.
Khanna S; Kirwan P; Naftalin NJ; Aukett RJ
Clin Radiol; 1986 Mar; 37(2):187-91. PubMed ID: 3698507
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
30. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin, adriamycin and cyclophosphamide (PACe) combination chemotherapy in patients with ovarian carcinoma resistant to chlorambucil.
Mead GM; Williams CJ; Whitehouse JM
Cancer Chemother Pharmacol; 1985; 15(2):179-80. PubMed ID: 3839443
[TBL] [Abstract][Full Text] [Related]
33. Serum albumin: its relationship to marrow and renal toxicity from platinum-based combination chemotherapy.
Belinson JL; Jarrell MA; McClure M; Kulig PM; Badger GJ
Gynecol Oncol; 1990 Apr; 37(1):93-5. PubMed ID: 2323620
[TBL] [Abstract][Full Text] [Related]
34. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
35. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer.
Bertelsen K; Hansen MK; Pedersen PH; Larsen G; Nyland M; Jacobsen M; Andersen JE
Br J Obstet Gynaecol; 1988 Dec; 95(12):1231-6. PubMed ID: 3224088
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study.
Creasman WT; Omura GA; Brady MF; Yordan E; DiSaia PJ; Beecham J
Gynecol Oncol; 1990 Dec; 39(3):239-43. PubMed ID: 2258063
[TBL] [Abstract][Full Text] [Related]
37. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
Gershenson DM; Copeland LJ; Kavanagh JJ; Stringer CA; Saul PB; Wharton JT
Obstet Gynecol; 1987 Nov; 70(5):765-9. PubMed ID: 3658288
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy for stage III-IV ovarian cancer: the CAP-regimen in previously untreated patients.
Meerpohl HG; Pfleiderer A; Kleine W; Teufel G
Onkologie; 1982 Oct; 5(5):238-41. PubMed ID: 6760025
[TBL] [Abstract][Full Text] [Related]
39. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
[TBL] [Abstract][Full Text] [Related]
40. Treatment of advanced ovarian cancer with sequential combination chemotherapy.
Griffin TW; Hunter RA; Cederbaum AI; Tak WK; Ward AD; Schwartz JH; Halpin TF; Strauss GM; Meyer RN; Liepman MK
Cancer; 1987 Nov; 60(9):2150-5. PubMed ID: 2830953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
